Table 1.
Clinic-Pathologic Characteristics of the Patients in the Primary Cohort
| Parameters | Total | Low GEP group | High GEP Group | P value |
|---|---|---|---|---|
| Age, years, mean (SD) | 53.3(11.4) | 52.7(11.9) | 53.9(10.8) | 0.420 |
| Gender | 0.543 | |||
| Male | 241(89.9%) | 122(91.0%) | 119(88.8%) | |
| Female | 27(10.1%) | 12(9.0%) | 15(11.2%) | |
| Lesion size, cm, median (IQR) | 5.1 (3.6,8.5) | 5.6 (3.7,9.2) | 4.6 (3.3,7.4) | 0.012* |
| Lesion number | 0.329 | |||
| 1 | 250(93.3%) | 123(91.8%) | 127(94.8%) | |
| ≥2 | 18(6.7%) | 11(8.2%) | 7(5.2%) | |
| Liver cirrhosis | 0.902 | |||
| Positive | 147(54.9%) | 73(54.5%) | 74(55.2%) | |
| Negative | 121(45.1%) | 61(45.5%) | 60(44.8%) | |
| CEA, ug/L | 0.669 | |||
| <5 | 244(91.0%) | 123(91.8%) | 121(90.3%) | |
| ≥5 | 24(9.0%) | 11(8.2%) | 13(9.7%) | |
| AFP, ug/L | 0.699 | |||
| <400 | 177(66.0%) | 90(67.2%) | 87(64.9%) | |
| ≥400 | 91(34.0%) | 44(32.8%) | 47(35.1%) | |
| HBsAg | 0.859 | |||
| Positive | 231(86.2%) | 115(85.8%) | 116(86.6%) | |
| Negative | 37(13.8%) | 19(14.2%) | 18(13.4%) | |
| WBC, 10^9/L | 1.000 | |||
| <10 | 261(97.4%) | 130(97.0%) | 131(97.8%) | |
| ≥10 | 7(2.6%) | 4(3.0%) | 3(2.2%) | |
| NE% | 0.758 | |||
| <0.75 | 257(95.9%) | 129(96.3%) | 128(95.5%) | |
| ≥0.75 | 11(4.1%) | 5(3.7%) | 6(4.5%) | |
| PLT, 10^9/L | 0.155 | |||
| <100 | 27(10.1%) | 10(7.5%) | 17(12.7%) | |
| ≥100 | 241(89.9%) | 124(92.5%) | 117(87.3%) | |
| PT, S | 0.302 | |||
| <14 | 252(94.0%) | 128(95.5%) | 124(92.5%) | |
| ≥14 | 16(6.0%) | 6(4.5%) | 10(7.5%) | |
| TBIL, umol/L | 0.859 | |||
| <22 | 231(86.2%) | 116(86.6%) | 115(85.8%) | |
| ≥22 | 37(13.8%) | 18(13.4%) | 19(14.2%) | |
| DBIL, umol/L | 0.820 | |||
| <7 | 247(92.2%) | 124(92.5%) | 123(91.8%) | |
| ≥7 | 21(7.8%) | 10(7.5%) | 11(8.2%) | |
| ALB, g/L | 0.698 | |||
| <35 | 30(11.2%) | 14(10.4%) | 16(11.9%) | |
| ≥35 | 238(88.8%) | 120(89.6%) | 118(88.1%) | |
| ALT, U/L | 1.000 | |||
| <40 | 170(63.4%) | 85(63.4%) | 85(63.4%) | |
| ≥40 | 98(36.6%) | 49(36.6%) | 49(36.6%) | |
| AST, U/L | 0.539 | |||
| <37 | 149(55.6%) | 72(53.7%) | 77(57.5%) | |
| ≥37 | 119(44.4%) | 62(46.3%) | 57(42.5%) | |
| ALP, U/L | 0.217 | |||
| <110 | 216(80.6%) | 104(77.6%) | 112(83.6%) | |
| ≥110 | 52(19.4%) | 30(22.4%) | 22(16.4%) | |
| GGT, U/L | 0.460 | |||
| <50 | 118(44.0%) | 56(41.8%) | 62(46.3%) | |
| ≥50 | 150(56.0%) | 78(58.2%) | 72(53.7%) | |
| BCLC stage | 0.245 | |||
| 0 | 7(2.6%) | 2(1.5%) | 5(3.7%) | |
| A | 171(63.8%) | 80(59.7%) | 91(67.9%) | |
| B | 11(4.1%) | 6(4.5%) | 5(3.7%) | |
| C | 79(29.5%) | 46(34.3%) | 33(24.6%) |
Notes: Continuous variables were presented in mean with standard deviation or median with interquartile rage. Categorical variables are presented as n (%). * p < 0.05.
Abbreviations: SD, standard deviation; IQR, inter-quartile range; CEA, carcinoembryonic antigen, AFP, alpha fetoprotein, HBsAg, hepatitis B virus surface antigen, WBC, white blood cell, NE%, neutrophil ratio, PLT, platelet, PT, prothrombin time, TBIL, total bilirubin, DBIL, direct bilirubin, ALB, albumin, ALT, alanine aminotransferase, AST, aspartate aminotransferase, ALP, alkaline phosphatase, GGT, gamma-glutamyl transferase, BCLC, Barcelona Clinic Liver Cancer.